List of Excipients in Branded Drug SYNDROS

Syndros Excipient Strategy and Commercial Opportunities in Dronabinol Oral Solution

Last updated: August 9, 2026

Syndros is a 5 mg/mL oral solution of dronabinol formulated with sesame oil, dehydrated alcohol, sucralose, and strawberry flavor. Its excipient strategy prioritizes cannabinoid solubilization, dose uniformity, palatability, and administration of small volumes through an oral syringe. The main commercial opportunities are improved excipient systems, alcohol-free formulations, allergen-reduced vehicles, pediatric-friendly presentations, and alternative cannabinoid oral liquids. Regulatory and patent barriers include Schedule II controls, formulation stability requirements, cannabinoid-specific intellectual property, and the need to demonstrate bioequivalence for generic substitution.[1]

What is Syndros and how is it formulated?

Syndros is the brand name for dronabinol oral solution. Dronabinol is synthetic delta-9-tetrahydrocannabinol, or THC. The product is approved for:

• Anorexia associated with weight loss in patients with AIDS
• Nausea and vomiting associated with cancer chemotherapy in patients who have failed adequate antiemetic treatment

Each milliliter contains 5 mg of dronabinol. The product is administered orally using a graduated oral syringe supplied with the commercial package.[1]

Syndros formulation composition

Component	Function in the formulation
Dronabinol	Active pharmaceutical ingredient
Sesame oil	Lipid vehicle and primary solubilizing medium
Dehydrated alcohol	Cosolvent and potential antimicrobial-supporting excipient
Sucralose	High-intensity sweetener
Strawberry flavor	Taste-masking and patient acceptability
Purified water, if present in the final formulation process	Processing and formulation control, subject to the approved label and manufacturing specification

The FDA-approved label identifies sesame oil, dehydrated alcohol, sucralose, and strawberry flavor as inactive ingredients. The product is a nonaqueous oral solution rather than an aqueous suspension or conventional capsule.[1]

Why does Syndros use sesame oil and alcohol?

Dronabinol has poor water solubility and is highly lipophilic. A lipid-based vehicle allows the active ingredient to remain dissolved at the labeled concentration. Sesame oil provides the principal nonaqueous phase, while ethanol functions as a cosolvent that can improve drug solubilization and facilitate manufacturing.

The excipient combination also addresses dose uniformity. A solution is generally easier to dose consistently than a suspension, provided the active remains chemically and physically stable throughout shelf life. That characteristic is commercially relevant for patients who have difficulty swallowing capsules or who require flexible liquid dosing.

The formulation has tradeoffs:

• Sesame oil can create allergen-labeling and patient-acceptability issues.
• Ethanol can limit suitability for some pediatric, geriatric, hepatic, or substance-sensitive populations.
• Lipid vehicles may require careful control of oxidation, container compatibility, and fill-volume accuracy.
• THC taste and psychoactive effects remain barriers even when sweeteners and flavors are used.
• A nonaqueous formulation can complicate cleaning validation and manufacturing scale-up.

What excipient functions are commercially important in Syndros?

Solubilization and dose uniformity

The first commercial requirement is maintaining dronabinol in solution at 5 mg/mL. A replacement vehicle must support:

• Chemical stability of dronabinol
• No precipitation during storage
• Consistent concentration after repeated bottle withdrawals
• Compatibility with the oral syringe
• Acceptable viscosity and pourability
• Protection from light, oxygen, and temperature excursions

Potential formulation platforms include medium-chain triglycerides, refined vegetable oils, oleic-acid-based systems, self-emulsifying drug delivery systems, and mixed lipid-cosolvent vehicles. Each alternative would require comparative stability and bioavailability work.

Taste masking

Dronabinol has a strong cannabinoid-associated taste profile. Sucralose and strawberry flavor provide a simple taste-masking system, but the commercial opportunity remains substantial because taste affects adherence and repeat use.

Potential strategies include:

• Ion-pairing or complexation
• Cyclodextrin-based masking
• Lipid encapsulation
• Flavor layering rather than single-flavor masking
• Polymer-coated microparticles
• Microemulsions that reduce direct contact between drug and taste receptors

Taste masking is more valuable when the product is used repeatedly or in patients with nausea, cachexia, mucositis, or altered taste perception.

Alcohol reduction or elimination

Dehydrated alcohol supports solubilization, but an alcohol-free product could expand the addressable market. Potential buyers include hospitals, pediatric specialists, long-term-care providers, and patients who avoid ethanol for medical, behavioral, religious, or personal reasons.

An alcohol-free formulation would need to preserve:

• Dronabinol concentration
• Physical stability
• Microbiological quality
• Dose uniformity
• Palatability
• Compatibility with the primary container and oral syringe

Removing ethanol is not a simple excipient substitution. The product may require a different lipid system, surfactant combination, or self-emulsifying delivery platform. Any material change could affect absorption and would likely require a regulatory comparability or new drug application strategy.

What formulation patents could protect a Syndros competitor?

The highest-value formulation claims would cover the composition and performance of the oral solution. Potential claim categories include:

Patent area	Commercial subject matter
Lipid vehicle	Specific oils, triglycerides, or mixed lipid systems that dissolve dronabinol
Cosolvent system	Ethanol-containing or ethanol-free solvent combinations
Surfactant system	Self-emulsifying or microemulsion formulations
Taste masking	Sweetener, flavor, complexation, coating, or encapsulation systems
Stability	Oxidation control, light protection, precipitation prevention, and shelf life
Dosing system	Bottle, adapter, syringe, and dose-delivery configuration
Patient population	Pediatric, geriatric, dysphagia, chemotherapy, or AIDS-related use
Manufacturing method	Mixing order, temperature controls, filtration, deaeration, and filling
Combination therapy	Dronabinol with antiemetics, appetite stimulants, or supportive-care agents

A competitor should not rely only on active-ingredient claims. Dronabinol is an established active pharmaceutical ingredient, and composition-of-matter protection for the drug itself is not the principal barrier. Commercial differentiation is more likely to come from formulation, device, manufacturing, use, or regulatory exclusivity.

What is the Orange Book status of Syndros?

Syndros is an FDA-approved prescription drug listed in the Orange Book. The product is a small-molecule drug, not a biologic, so biosimilar rules do not apply. Generic competition would proceed through an abbreviated new drug application, subject to the product’s listed patents, exclusivities, and regulatory requirements.[2]

The FDA Orange Book should be used to verify the current:

• Marketing status
• Reference listed drug designation
• Patent listings
• Pediatric exclusivity
• Exclusivity codes
• Therapeutic-equivalence status of approved alternatives

Orange Book entries can change through patent-listing updates, delistings, litigation outcomes, and FDA administrative actions. A current diligence review should rely on the live FDA database rather than historical patent summaries.

When does Syndros lose exclusivity?

Syndros was approved by the FDA in July 2016. Its approval pathway was a 505(b)(2) new drug application rather than a standard generic application. FDA approval of a 505(b)(2) product can provide regulatory exclusivity separate from patent protection, depending on the statutory basis and the approved indications.[3]

The relevant commercial dates are:

Event	Date or status
FDA approval	July 2016
Product type	Small-molecule oral solution
Regulatory pathway	505(b)(2) NDA
Controlled-substance status	Schedule II
Generic pathway	ANDA, subject to FDA requirements
Patent expiry	Must be confirmed from the current Orange Book and patent records
Biosimilar pathway	Not applicable

The date of FDA approval does not establish the date of commercial generic entry. Market entry depends on the combination of regulatory exclusivity, listed patents, Paragraph IV litigation, settlement terms, pediatric extensions, and any applicable 30-month stay.

How do Paragraph IV challenges affect Syndros?

A generic applicant can file a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed. The branded sponsor may then file patent litigation within the statutory period, potentially triggering a 30-month stay of FDA approval under the Hatch-Waxman framework.[4]

For Syndros, a Paragraph IV strategy would likely focus on:

• Whether the generic oral solution uses the same or a materially different excipient system
• Whether the proposed product infringes formulation claims
• Whether listed patents properly cover the approved product
• Whether the generic can establish bioequivalence
• Whether manufacturing-process claims are implicated
• Whether the proposed label avoids method-of-use claims

A generic applicant may seek a non-infringement position by using a different oil, eliminating ethanol, changing the flavor system, or adopting a different solubilization mechanism. Those changes may reduce patent exposure but can create new bioequivalence, stability, and quality risks.

What generic entry risks exist for Syndros?

Generic entry risk is moderate to high over the long term because the active ingredient is well characterized and the dosage form is an oral liquid. The principal barriers are formulation-specific rather than biological.

Technical barriers

An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence. For a lipophilic oral solution, the sponsor must control:

• Dronabinol assay and related substances
• Uniformity across the bottle and dose withdrawals
• In-use stability after opening
• Excipient compatibility
• Container closure integrity
• Oral-syringe dose accuracy
• Pharmacokinetic comparability

A generic solution may not be able to rely on a simple proportionality argument if its vehicle materially changes absorption. Lipid composition, ethanol concentration, viscosity, and surfactant content can affect dissolution, gastric dispersion, intestinal absorption, and food effects.

Legal barriers

Patent risk depends on the current listed patents and any unlisted claims that can support litigation under applicable law. Possible disputes may involve:

• Composition claims
• Stability claims
• Method-of-use claims
• Device claims
• Manufacturing claims
• Patent-listing eligibility

A generic applicant could also pursue a Paragraph III certification, agreeing to wait until patent expiry, or file a section viii statement carving out protected uses where permitted.

What commercial opportunities exist in Syndros excipients?

Alcohol-free dronabinol oral solution

An alcohol-free product has the clearest formulation opportunity. The target markets include pediatric and institutional care, although the approved indications and controlled-substance restrictions remain important limitations.

A successful product would need a replacement solvent system that provides equivalent or superior stability without increasing precipitation, viscosity, microbial risk, or unpleasant taste.

Allergen-reduced lipid vehicle

Sesame oil is a functional vehicle, but a manufacturer could pursue a formulation based on medium-chain triglycerides or another pharmaceutically acceptable lipid. The value proposition would include:

• Reduced sesame-allergen concern
• More consistent raw-material specifications
• Improved oxidation control
• Potentially better global sourcing
• Easier positioning for hospital formularies

The replacement vehicle would require a full assessment of chemical stability, bioequivalence, labeling, and patent clearance.

Pediatric and geriatric presentations

Patients with swallowing impairment are natural users of oral liquids, but the current indications do not automatically support broad pediatric use. A lower-volume, lower-alcohol, palatable formulation could support hospital use and future clinical development if a sponsor pursues appropriate indications.

Commercial features could include:

• Smaller dose increments
• Tamper-evident unit-dose packages
• Oral syringes with low dead space
• Flavor options
• Reduced excipient burden
• Clear dosing instructions for caregivers

Hospital and specialty-pharmacy packaging

Controlled-substance handling creates demand for packaging that reduces diversion and dosing errors. Opportunities include:

• Unit-dose oral syringes
• Serialized bottles
• Integrated adapters
• Child-resistant closures
• Low-residual-volume syringes
• Pharmacy-ready cartons
• Tamper-evident packaging

Packaging claims can provide supplementary intellectual-property protection, although they are less durable than formulation claims if competitors can use standard delivery systems.

Cannabinoid platform technology

A validated excipient platform for dronabinol could be extended to other lipophilic cannabinoids and cannabinoid combinations. Potential platform assets include:

• Self-emulsifying systems
• Nanoemulsions
• Solid-lipid particles
• Cyclodextrin complexes
• Buccal or sublingual liquids
• Long-acting injectable systems

The platform value depends on whether it produces a meaningful clinical or commercial advantage, such as faster onset, lower variability, reduced food effect, improved adherence, or lower dose.

How does Syndros compare with Marinol?

Syndros and Marinol contain dronabinol but use different dosage forms.

Attribute	Syndros	Marinol
Dosage form	Oral solution	Capsules
Strength	5 mg/mL	Multiple capsule strengths
Vehicle	Sesame oil and cosolvent system	Capsule formulation
Dose flexibility	High	Limited to capsule increments
Swallowing burden	Lower	Higher for patients with dysphagia
Excipient opportunity	Vehicle, taste, stability, device	Capsule shell, fill formulation, release profile
Generic substitution	Oral-solution competition	Capsule competition
Biosimilar relevance	None	None

Syndros has a delivery-format advantage for patients who cannot swallow capsules, while Marinol benefits from the familiarity and simplicity of a solid oral dosage form. The two products do not automatically substitute on a milligram-for-milligram basis from a regulatory or clinical perspective.

What FDA regulatory issues affect Syndros excipient development?

A formulation change may require a new drug application, a supplement, or an ANDA strategy depending on the sponsor’s relationship to the reference product and the scope of the change. FDA scrutiny is likely to focus on:

• Pharmaceutical equivalence
• Bioequivalence
• Excipient safety
• Stability
• Microbiological quality
• Labeling
• Dosing accuracy
• Controlled-substance security
• Manufacturing controls

The FDA’s product-specific guidance and general recommendations for orally administered immediate-release products are relevant to generic development. The sponsor must also assess whether a novel excipient, new route of administration, or materially different exposure profile removes the ability to rely on an abbreviated pathway.[5]

What manufacturing and IP barriers affect commercial entry?

Manufacturing barriers are manageable but important. A commercial-scale producer must control cannabinoid potency, solvent removal or retention, lipid oxidation, mixing homogeneity, filling accuracy, and cleaning of equipment exposed to a potent, oily active ingredient.

Key manufacturing controls include:

• Closed handling of dronabinol
• Validated weighing and dispensing
• Controlled addition sequence for excipients
• Protection from light and oxygen
• In-process assay testing
• Filter compatibility
• Homogeneous filling
• Container closure validation
• Controlled-substance inventory reconciliation

The strongest IP position would combine formulation claims with manufacturing and device claims. A competitor using a different excipient system may avoid some formulation claims but still face process or use patents. Freedom-to-operate analysis should review U.S. patents, pending applications, continuation filings, international families, and litigation records.

Key Takeaways

• Syndros is a 5 mg/mL dronabinol oral solution approved in 2016.
• Sesame oil is the principal lipid vehicle; dehydrated alcohol supports solubilization.
• Sucralose and strawberry flavor address palatability but do not eliminate cannabinoid taste.
• The most attractive formulation opportunity is an alcohol-free or sesame-oil-free oral solution.
• Generic risk is driven by formulation bioequivalence, patent listings, and controlled-substance requirements.
• Syndros is subject to small-molecule Hatch-Waxman competition, not biosimilar competition.
• Device, packaging, stability, taste-masking, and manufacturing patents can supplement formulation claims.
• Current Orange Book listings and patent expirations must be confirmed from the FDA’s active database before transaction or litigation decisions.

FAQs

Can a generic company use a different excipient from Syndros?

Yes. A generic applicant may use different inactive ingredients if the product remains pharmaceutically equivalent, meets FDA inactive-ingredient requirements, and demonstrates bioequivalence. A different vehicle can create new stability, absorption, and patent-clearance issues.

Is sesame oil essential to the Syndros formulation?

Sesame oil is part of the approved formulation, but it is not necessarily essential to every future dronabinol oral solution. A substitute lipid could be developed if it maintains solubility, stability, dose uniformity, safety, and comparable drug exposure.

Does Syndros contain a biosimilar risk?

No. Dronabinol is a synthetic small molecule. Competition would arise through generic or other small-molecule regulatory pathways rather than the biosimilar framework.

Could an alcohol-free dronabinol product receive separate market protection?

Potentially. Protection could arise from formulation patents, regulatory exclusivity associated with a new indication or dosage form, or both. The scope and duration would depend on the specific development program and granted claims.

What is the most defensible patent strategy for a Syndros competitor?

A layered strategy is strongest. It should combine claims directed to an improved solvent or lipid system, taste masking, stability, manufacturing, dosing hardware, and a differentiated clinical use where supported by data.